NeuroOne Medical Technologies Corporation (NMTC)
NASDAQ: NMTC · Real-Time Price · USD
0.7950
-0.0070 (-0.87%)
At close: Apr 2, 2026, 4:00 PM EDT
0.8109
+0.0159 (2.00%)
After-hours: Apr 2, 2026, 4:30 PM EDT
NMTC Revenue
NeuroOne Medical Technologies had revenue of $2.89M in the quarter ending December 31, 2025, a decrease of -53.90%. This brings the company's revenue in the last twelve months to $8.72M, down -0.38% year-over-year. In the fiscal year ending September 30, 2025, NeuroOne Medical Technologies had annual revenue of $12.10M with 250.35% growth.
Revenue (ttm)
$8.72M
Revenue Growth
-0.38%
P/S Ratio
3.44
Revenue / Employee
$650,898
Employees
18
Market Cap
40.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 12.10M | 8.64M | 250.35% |
| Sep 30, 2024 | 3.45M | 45.37K | 1.33% |
| Sep 30, 2023 | 3.41M | 1.29M | 60.73% |
| Sep 30, 2022 | 2.12M | 1.88M | 772.60% |
| Sep 30, 2021 | 242.96K | -1.68M | -87.39% |
| Sep 30, 2020 | 1.93M | - | - |
| Sep 30, 2019 | - | - | - |
| Sep 30, 2018 | - | - | - |
| Jun 30, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Sep 30, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Sep 30, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Sep 30, 2015 | -113.00 | -886.00 | - |
| Dec 31, 2014 | 773.00 | -476.00 | -38.11% |
| Dec 31, 2013 | 1.25K | 328.00 | 35.61% |
| Dec 31, 2012 | 921.00 | -4.48K | -82.94% |
| Dec 31, 2011 | 5.40K | 4.23K | 362.55% |
| Dec 31, 2010 | 1.17K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Accuray | 436.97M |
| Nortech Systems | 118.37M |
| Pulmonx | 90.50M |
| TELA Bio | 80.28M |
| Cytosorbents | 37.06M |
| electroCore | 32.03M |
| Spectral AI | 19.65M |
| Elutia | 12.29M |
NMTC News
- 7 months ago - NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025 - GlobeNewsWire
- 8 months ago - NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain - GlobeNewsWire
- 8 months ago - NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9% - GlobeNewsWire
- 8 months ago - NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - Update - GlobeNewsWire
- 8 months ago - NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - GlobeNewsWire
- 9 months ago - NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office - GlobeNewsWire
- 10 months ago - NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System - GlobeNewsWire
- 10 months ago - NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary - GlobeNewsWire